苏宁环球股份有限公司 2025 年半年度报告摘要 证券代码：000718 证券简称：苏宁环球 公告编号：2025-024 苏宁环球股份有限公司 【2025 年 8 月】 苏宁环球股份有限公司 2025 年半年度报 告摘要 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划， 投资者应当到 证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 ?不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 ?适用 □不适用 是否以公积金转增股本 □是 ?否 公司经本次董事会审议通过的利润分配预案为：以 3,034,636,384 股为基数，向全体股东每 10 股派 发现金红利 董事会决议通过的本报告期优先股利润分配预案 □适用 ?不适用 二、公司基本情况 股票简称 苏宁环球 股票代码 000718 股票上市交易所 深圳证券交易所 联系人和联系方式 董事会秘书 证券事务 代表 姓名 蒋立波 王燕 南京市鼓楼区集庆门大街 270 号苏宁 南京市鼓楼区集庆门 大街 270 号苏宁 办公地址 环球国际中心 49 楼 ...

Group 1: Medical Aesthetics Business Development - The company plans to increase investment in the medical aesthetics sector, aiming to enhance the market recognition and reputation of the Suya Medical Aesthetics brand. In 2025, new medical aesthetics institutions are planned to open in Jiangsu and Shanghai [2][3] - In 2024, the medical aesthetics segment achieved revenue of 179 million yuan and is currently profitable. The company will continue to focus on self-built facilities and expand in high-consumption areas like the Yangtze River Delta [5][6] Group 2: Shareholder Engagement and Stock Performance - In 2024, the actual controller and some executives completed a round of share buybacks, demonstrating confidence in the company's long-term investment value [3][4] - The company is committed to a "long-termism" approach, focusing on stable operations and long-term value creation, despite current market pressures affecting stock prices [4][6] Group 3: Strategic Business Direction - The company is dedicated to developing medical aesthetics and biopharmaceuticals, emphasizing a long-term strategy and resource optimization to enhance operational efficiency and profitability [3][5] - Future business expansion will include exploring new industries and opportunities, with a focus on maintaining a balanced approach to growth and avoiding reckless expansion [5][6] Group 4: Market Conditions and Company Response - The company's stock price has been under pressure due to macroeconomic factors, industry developments, and investor expectations. The company aims to improve product quality, brand building, and customer service to enhance overall competitiveness [6][7] - New medical aesthetics facilities are under construction, with plans for trial operations expected around mid-year [6][7]